e-Drug3D

1845

RIBOCICLIB

INN
RIBOCICLIB

cas 1211441-98-3

CLASS

ANTINEOPLASTIC
TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
KINASE INHIBITOR
INHIBITOR OF CYCLIN-DEPENDENT KINASE (CDK) 4 AND 6

ROUTE (list)

ORAL

ATC code

L01EF02

PK parameters

Tmax 2.5 HOUR
VD 1090 LITER
Cl 25.5 LITER / HOUR
PPB 70 PERCENT
t1/2 32 HOUR

Target

TARGET CDK-4
CDK-6

PDB
5L2T (THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.)

Ligand code = 6ZZ (link to the list of PDB complexes)

Download experimental 3D coordinates of 6ZZ with added hydrogens

DrugCentral

Cyclin-dependent kinase 6 UNIPROT Q00534 CDK6

Cyclin-dependent kinase 4 UNIPROT P11802 CDK4

Download SDF file

7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-

Formula:
C23H30N8O

Calculated chemical properties:

MW 434.55
NB_atoms 32
XLogP 2.80
PSA 75.934
NB_HD 2
NB_HA 9
fsp3 0.48
Lipinski(0=no;1=yes) 1

FDA
NDA 209092 (label) INN (RIBOCICLIB SUCCINATE) KISQALI (NOVARTIS) APPROVAL= AP YEAR= 2017
NDA 209935 (label) INN (LETROZOLE ; RIBOCICLIB SUCCINATE) KISQALI FEMARA CO-PACK COPACKAGED (NOVARTIS) APPROVAL= AP YEAR= 2017
NDA 215975 (pdf not found) INN (LETROZOLE ; RIBOCICLIB SUCCINATE) LETROZOLE;VRIBOCICLIB SUCCINATE (MSN LABS PVT LTD) APPROVAL= TA YEAR= 2023
NDA 215677 (pdf not found) INN (RIBOCICLIB) RIBOCICLIB (ALEMBIC PHARMS LTD) APPROVAL= TA YEAR= 2024